{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:25:52Z","timestamp":1777573552233,"version":"3.51.4"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder, which severely impairs the quality of life of patients. Treatment of refractory IBS patients is needed, but it is not yet widely available. Therefore, we previously developed a Japanese version of cognitive behavioral therapy with interoceptive exposure (CBT-IE) involving 10 face-to-face sessions to treat refractory IBS patients. To disseminate this treatment of IBS in places where therapists are limited, we further developed a hybrid CBT-IE program with complementary video materials that include psychoeducation and homework instructions so that patients can prepare for face-to-face sessions in advance at home and the session time can be shortened, thereby reducing the burden on both patient and therapist. In this study, we conducted a trial to evaluate the feasibility, efficacy, and safety of the hybrid CBT-IE program for Japanese IBS patients. The study was a single-arm, open-label pilot clinical trial. A total of 16 IBS patients were included in the study and 14 patients completed the intervention, which consisted of 10 weekly individual hybrid CBT-IE sessions. We performed an intention to treat analysis. The primary outcome measure for the efficacy of the intervention was a decrease in the severity of IBS symptoms. The feasibility and safety of the intervention were examined by the dropout rate and recording of adverse events, respectively. The dropout rate of the hybrid CBT-IE was comparable to that of our previous CBT-IE with only face-to-face sessions and no adverse events were recorded. The severity of IBS symptoms within-group was significantly decreased from the baseline to mid-treatment [Hedges' g = \u22120.98 (\u22121.54, \u22120.41)], post-treatment [Hedges' g = \u22121.48 (\u22122.09, \u22120.88)], 3-month follow-up [Hedges' g = \u22121.78 (\u22122.41, \u22121.14)], and 6-month follow-up [Hedges' g = \u22121.76 (\u22122.39, \u22121.13)]. Our results suggest that the hybrid CBT-IE is effective and could be conducted safely. To confirm the effectiveness of the hybrid CBT-IE, it is necessary to conduct a multicenter, parallel-design randomized control trial.<\/jats:p><jats:p><jats:bold>Clinical Trial Registration:<\/jats:bold> [<jats:ext-link>https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr\/ctr_view.cgi?recptno=R000041376<\/jats:ext-link>], identifier [UMIN000036327].<\/jats:p>","DOI":"10.3389\/fpsyt.2021.673939","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T10:24:25Z","timestamp":1631183065000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Hybrid Cognitive Behavioral Therapy With Interoceptive Exposure for Irritable Bowel Syndrome: A Feasibility Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Misako","family":"Funaba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Kawanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koyo","family":"Higami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitoshi","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushi","family":"Maruo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Oe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satsuki","family":"Kura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Horikoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisato","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroe","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Ariga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Fukudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Sekiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/nrdp.2016.14","article-title":"Irritable bowel syndrome","volume":"2","author":"Enck","year":"2016","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1046\/j.1365-2036.2002.01290.x","article-title":"Health-related quality of life among persons with irritable bowel syndrome: a systematic review","volume":"16","author":"El-Serag","year":"2002","journal-title":"Aliment Pharmacol Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/0091217417749791","article-title":"Irritable bowel syndrome and quality of life in a community-dwelling population in Japan","volume":"53","author":"Sugawara","year":"2018","journal-title":"Int J Psychiatry Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","article-title":"Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study","volume":"160","author":"Sperber","year":"2021","journal-title":"Gastroenterology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/gut.41.4.505","article-title":"Evidence for two distinct perceptual alterations in irritable bowel syndrome","volume":"41","author":"Naliboff","year":"1997","journal-title":"Gut."},{"key":"B6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0304-3959(01)00285-8","article-title":"Hypersensitivity to visceral and cutaneous pain in the irritable bowel syndrome","volume":"93","author":"Verne","year":"2001","journal-title":"Pain."},{"key":"B7","first-page":"28","article-title":"Depression, anxiety, and the gastrointestinal system","volume":"62","author":"Mayer","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1097\/00006842-200109000-00001","article-title":"Interoception: the inside story\u2014a model for psychosomatic processes","volume":"63","author":"Cameron","year":"2001","journal-title":"Psychosom Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/scan\/nss108","article-title":"Anterior insular cortex mediates bodily sensibility and social anxiety","volume":"8","author":"Terasawa","year":"2013","journal-title":"Soc Cogn Affect Neurosci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1365-2036.2004.02007.x","article-title":"The visceral sensitivity index: development and validation of a gastrointestinal symptom-specific anxiety scale","volume":"20","author":"Labus","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0022-3999(03)00019-9","article-title":"Prevalence of irritable bowel syndrome among university students: the roles of worry, neuroticism, anxiety sensitivity and visceral anxiety","volume":"55","author":"Hazlett-Stevens","year":"2003","journal-title":"J Psychosom Res."},{"key":"B12","first-page":"A","article-title":"Gastrointestinal-specific anxiety: further validation of the visceral sensitivity index","volume":"128","author":"Labus","year":"2005","journal-title":"Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jpsychores.2007.10.010","article-title":"The role of stress in symptom exacerbation among IBS patients","volume":"64","author":"Blanchard","year":"2008","journal-title":"J Psychosom Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"G519","DOI":"10.1152\/ajpgi.2001.280.4.G519","article-title":"Stress and irritable bowel syndrome","volume":"280","author":"Mayer","year":"2001","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00535-014-1017-0","article-title":"Evidence-based clinical practice guidelines for irritable bowel syndrome","volume":"50","author":"Fukudo","year":"2015","journal-title":"J Gastroenterol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00535-020-01746-z","article-title":"Evidence-based clinical practice guidelines for irritable bowel syndrome 2020","volume":"56","author":"Fukudo","year":"2021","journal-title":"J Gastroenterol."},{"key":"B17","unstructured":"Irritable Bowel Syndrome in Adults: Diagnosis and Management of Irritable Bowel Syndrome in Primary Care2008"},{"key":"B18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.brat.2011.04.001","article-title":"A cognitive-behavioral treatment for irritable bowel syndrome using interoceptive exposure to visceral sensations","volume":"49","author":"Craske","year":"2011","journal-title":"Behav Res Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/(SICI)1099-0879(199712)4:4<226::AID-CPP129>3.0.CO;2-M","article-title":"Attention training: effects on anxiety and beliefs in panic and social phobia","volume":"4","author":"Wells","year":"1997","journal-title":"Clin Psychol Psychother"},{"key":"B20","first-page":"630","article-title":"Development of cognitive behavior therapy for irritable syndrome (CBT-IE): a pilot study in Japan","volume":"56","author":"Oe","year":"2016","journal-title":"Jpn J Psychosom Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1053\/j.gastro.2006.03.008","article-title":"The functional gastrointestinal disorders and the Rome III process","volume":"130","author":"Drossman","year":"2006","journal-title":"Gastroenterology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1752-8062.2011.00347.x","article-title":"Recommendations for planning pilot studies in clinical and translational research","volume":"4","author":"Moore","year":"2011","journal-title":"Clin Transl Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13030-019-0155-2","article-title":"Cognitive behavioral therapy with interoceptive exposure and complementary video materials for irritable bowel syndrome (IBS): protocol for a multicenter randomized controlled trial in Japan","volume":"13","author":"Kawanishi","year":"2019","journal-title":"Biopsychosoc Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","article-title":"The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress","volume":"11","author":"Francis","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00535-006-1799-9","article-title":"Validation of the Japanese version of the Rome II modular questionnaire and irritable bowel syndrome severity index","volume":"41","author":"Shinozaki","year":"2006","journal-title":"J Gastroenterol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1751-0759-8-10","article-title":"Gastrointestinal specific anxiety in irritable bowel syndrome: validation of the Japanese version of the visceral sensitivity index for university students","volume":"8","author":"Saigo","year":"2014","journal-title":"Biopsychosoc Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1751-0759-1-6","article-title":"Translation and validation of a Japanese version of the irritable bowel syndrome-quality of life measure (IBS-QOL-J)","volume":"1","author":"Kanazawa","year":"2007","journal-title":"Biopsychosoc Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S0895-4356(98)00095-X","article-title":"Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan","volume":"51","author":"Fukuhara","year":"1998","journal-title":"J Clin Epidemiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2466\/pms.1989.69.2.611","article-title":"The Japanese State-Trait Anxiety Inventory: age and sex differences","volume":"69","author":"Nakazato","year":"1989","journal-title":"Percept Mot Skills"},{"key":"B30","first-page":"38","volume-title":"BDI-II, Beck Depression Inventory: Manual","author":"Beck","year":"1996"},{"key":"B31","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0165-1781(02)00106-3","article-title":"Cross-cultural validation of the Beck Depression Inventory-II in Japan","volume":"110","author":"Kojima","year":"2002","journal-title":"Psychiatry Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1023\/A:1024159226274","article-title":"Validation of irritable bowel syndrome Global Improvement Scale: an integrated symptom end point for assessing treatment efficacy","volume":"48","author":"Gordon","year":"2003","journal-title":"Dig Dis Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1053\/j.gastro.2015.10.047","article-title":"Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women","volume":"150","author":"Fukudo","year":"2016","journal-title":"Gastroenterology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"A","DOI":"10.1097\/PSY.0000000000000835","article-title":"Predictors of response to interoceptive exposure-based cognitive-behavioral therapy (CBT-IE) in irritable bowel syndrome patients in Japan. In: abstracts of the 78th Annual Scientific Meeting of the American Psychosomatic Society (scheduled for March 2020; cancelled due to the COVID-19 pandemic)","volume":"82","author":"Funaba","year":"2020","journal-title":"Am Psychosom Soc"},{"key":"B35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jpsychores.2013.04.008","article-title":"Are self-administered or minimal therapist contact psychotherapies an effective treatment for irritable bowel syndrome (IBS): a systematic review","volume":"75","author":"Ahl","year":"2013","journal-title":"J Psychosom Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.brat.2014.01.007","article-title":"Provoking symptoms to relieve symptoms: a randomized controlled dismantling study of exposure therapy in irritable bowel syndrome","volume":"55","author":"Lj\u00f3tsson","year":"2014","journal-title":"Behav Res Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.brat.2010.10.006","article-title":"Long-term follow-up of internet-delivered exposure and mindfulness based treatment for irritable bowel syndrome","volume":"49","author":"Lj\u00f3tsson","year":"2011","journal-title":"Behav Res Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/j.gastro.2018.03.063","article-title":"Improvement in gastrointestinal symptoms after cognitive behavior therapy for refractory irritable bowel syndrome","volume":"155","author":"Lackner","year":"2018","journal-title":"Gastroenterology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.cgh.2018.10.033","article-title":"Factors associated with efficacy of cognitive behavior therapy vs. education for patients with irritable bowel syndrome","volume":"17","author":"Lackner","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12876-020-1157-z","article-title":"Group cognitive behavioural therapy (GCBT) vs. treatment as usual (TAU) in the treatment of irritable bowel syndrome (IBS): a study protocol for a randomized controlled trial","volume":"20","author":"Kikuchi","year":"2020","journal-title":"BMC Gastroenterol."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.03.019","article-title":"Efficacy and safety of 5-HT4 receptor agonist minesapride for irritable bowel syndrome with constipation in a randomized controlled trial","volume":"19","author":"Fukudo","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.7326\/0003-4819-155-1-201107050-00006","article-title":"Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study","volume":"155","author":"Dechartres","year":"2011","journal-title":"Ann Intern Med."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.673939\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T10:24:34Z","timestamp":1631183074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.673939\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":42,"alternative-id":["10.3389\/fpsyt.2021.673939"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.673939","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,9]]},"article-number":"673939"}}